Two different studies demonstrated a-methylacyl coenzyme A racemase (AMACR) to be a highly specific marker in Barrett's neoplastic lesions. Reactive atypia was positive in 3/30 cases in these studies. We present a retrospective study of early Barrett's adenocarcinoma treated with surgery (2000-2005, n ¼ 29; M:F ¼ 5:1, median age 67 years). We analyzed the role of AMACR expression in reactive and neoplastic lesions associated with the disease of 77 different specimens (60 biopsy and 17 surgical specimens) of these patients. In our cohort, 70% of cases demonstrated infiltration of the submucosa, 38% were poorly differentiated, and/or 31% demonstrated lymph vessel infiltration. We used a multi-tissue array, with reactive and neoplastic samples for each patient to analyze the immunoreactivity of AMACR. Barrett's epithelium that was negative for dysplasia and columnar epithelial cell changes indefinite for dysplasia (n ¼ 30) did not demonstrate AMACR immunoreactivity. AMACR immunoreactivity was demonstrated in 27% (8/30) of cases of Barrett's epithelium with columnar epithelial cell changes indefinite for dysplasia. Altogether 91% of cases with low-grade dysplasia were AMACR-positive and 96% of cases with high-grade dysplasia and early Barrett's adenocarcinoma were positive for AMACR. In summary, the sensitivity of AMACR expression in low-grade dysplasia and subsequent early Barrett's adenocarcinoma was significantly higher in our study compared with previous data. This might be a new diagnostic marker for dysplasia carcinoma sequence in Barrett's low-grade neoplastic lesions. Further studies are required to investigate this point with well-defined controls having at least 5-years follow-up.
The prevalence of Barrett's esophagus in patients with gastroesophageal reflux disease is 2.3-2.4%. 1, 2 This represents the most serious histological consequence of gastroesophageal reflux disease. Barrett's disease is an established precursor to esophageal adenocarcinoma. In Germany, the incidence of adenocarcinoma in Barrett's esophagus is 0.4-1.7%. 3 Although most patients with Barrett's esophagus do not progress to adenocarcinoma, those with progression have a poor prognosis. 4 Endoscopic resection has been recommended as a local curative approach for (unicentric) mucosal Barrett's adenocarcinoma (m1 or m2, and m3 without lymph vessel infiltration). 5 Surgery is still the therapy of choice in early Barrett's adenocarcinoma infiltrating submucosal layers or poorly differentiated tumors because of a higher risk of lymph-node metastasis. 6 Recently, two studies focused on a-methylacyl coenzyme A racemase (AMACR) in Barrett's neoplastic lesions, an enzyme known to be expressed in prostate and colon cancer. [7] [8] [9] AMACR catalyzes the racemization of a-methyl-branched carboxylic coenzyme A thioesters. This protein was originally identified in the mitochondria and peroxisomes of rat liver cells. 10 Previous studies demonstrated the expression of AMACR to be a highly specific marker in Barrett's neoplastic lesions. 7, 8 Columnar epithelial cell changes indefinite for dysplasia were positive in 3/30 cases in these studies. Follow-up was available for 11 of these patients with columnar epithelial cell changes indefinite for dysplasia. After 2 months, Barrett's adenocarcinoma was diagnosed in 1/3 AMACR immunoreactive columnar epithelial cell changes indefinite for dysplasia patients. There was no follow-up in the other two patients.
In this retrospective study, we analyzed 29 cases of early Barrett's adenocarcinoma treated with surgery. We immunohistochemically stained all cases with AMACR. The aim of this study is to analyze whether AMACR expression could be a new diagnostic marker for dysplasia carcinoma sequence in Barrett's low-grade neoplastic lesions.
Materials and methods

Cases
The 29 cases found in this retrospective study of early Barrett's adenocarcinoma treated with surgery were operated on between 2000 and 2005 (Table 1) . Overall, 133 lesions of Barrett's disease were analyzed in these 29 patients (M:F ¼ 5:1). From a total of 203 specimens taken from these 29 patients, 77 specimens (60 biopsy and 17 surgical specimens) were included in this study. The age at surgery ranged between 48 and 81 years (median age 67 years). The early cancers demonstrated were limited to mucosal carcinoma in 28% (8/29, pT1a; three m1, five m3) and infiltrated the submucosal layer in 72% (21/29, pT1b; seven sm1, two sm2, 12 sm3). In total 31% (9/29) demonstrated lymph vessel infiltration and 17% (5/29) showed positive lymph nodes (1-3 positive lymph nodes). The classification of tumor stage was performed on the basis that mucosa and submucosa were divided into three-thirds. The upper third was classified as level 1, middle third as level 2 and lower third as level 3 in mucosa and submucosa, respectively. The lymph-node status was determined by serial sections of each lymph node in 7-74 prepared nodes (mean: 27 lymph nodes per case) according to protocols used for sentinel lymph-node analysis in breast cancer. All nodal-positive cases demonstrated lymphatic vessel infiltration in the biopsy or endoscopic resection specimen.
Immunohistochemistry
We analyzed a multi-tissue array from each patient with reactive and neoplastic lesions of the disease by immunohistochemistry. There were 30 Barrett's epithelium negative for dysplasia and columnar epithelial cell changes indefinite for dysplasia (Barrett's epithelium), 30 Barrett's epithelium with columnar epithelial cell changes indefinite for dysplasia, 20 Barrett's epithelium with low-grade dysplasia, 23 Barrett's epithelium with highgrade dysplasia, and 24 early Barrett's adenocarcinoma. All columnar epithelial cell changes indefinite for dysplasia specimens of patients included in our cohort were examined in this study. The areas with Barrett's epithelium, columnar epithelial cell changes indefinite for dysplasia, low-grade dysplasia, or high-grade dysplasia we chose to examine in our study were not taken from the lateral margins of the invasive carcinoma. After deparaffinization, these arrays of formalin-fixed tissue sections (3-mm thick) were rehydrated, immersed in preheated target retrieval solution pH 9 (#S2367; Dako) and treated with heat for 20 min in a steamer. The slides were stained with the monoclonal anti-AMACR antibody p504S (clone 13H4, 1:500 dilution; Bioprime, Germany; Dako Autostainer; LSAB Detection System, #K5005). Two different pathologists evaluated the immunohistochemical stainings for the presence and the extent of AMACR expression in a blinded fashion, designating samples according to Lisovsky et al, 7 as negative (0 to o5% cells positive), 1 þ (5-14% of cells positive), 
Statistical Analysis
The sensitivity of AMACR for dysplasia (Table 2) was calculated as the fraction of biopsies with dysplasia that stained positively for AMACR. The specificity of AMACR for dysplasia (Table 2) was calculated as the fraction of biopsies considered negative for dysplasia that were also negative for AMACR. Biopsies graded as columnar epithelial cell changes indefinite for dysplasia were not included in specificity calculation, as by definition, columnar epithelial cell changes indefinite for dysplasia foci are not considered definitely negative for dysplasia. For each sensitivity and specificity an exact 95% confidence interval was given. A Wilcoxon test was performed to compare AMACR staining scores between two groups with poor tumor grade and lymph vessel invasion (data not shown).
Results
Immunohistochemistry
A total of 133 reactive and neoplastic lesions of Barrett's disease were analyzed. All lesions were stained with AMACR. AMACR was negative in biopsies negative for dysplasia (Barrett's epithelium; Figure 1a cases, endoscopic resection had previously been performed up to five times (median 0; mean 1) for high-grade dysplasia or mucosal adenocarcinoma in Barrett's esophagus. All data are summarized in Table 1 .
Lymph Vessel Infiltration and Poor Tumor Grade
AMACR staining scores were analyzed between two groups with poor tumor grade and lymph vessel invasion (L1/G 3 -positive versus AMACR expression in the dysplasia carcinoma sequence S Scheil-Bertram et al submucosal adenocarcinoma) before surgery. Surgery is still the therapy of choice in cases with Barrett's adenocarcinoma infiltrating submucosal layers because of a higher risk of lymphatic vessel infiltration. 6 In our cohort, none of the mucosal Barrett's adenocarcinomas (n ¼ 7) demonstrated lymphatic vessel infiltration or positive lymph nodes, and submucosal Barrett's adenocarcinomas demonstrated in 29% (sm1) and 50% (sm2/3) lymphatic vessel infiltration, whereas positive lymph nodes were found in 24% of submucosal adenocarcinomas (n ¼ 21; 14% sm1; 29% sm2/3). These data confirm the data recently published by Bollschweiler et al. 12 These authors examined 14 mucosal and 22 submucosal early adenocarcinomas in Barrett's disease. None of their mucosal cancers demonstrated positive lymph nodes, whereas 21% of submucosal cancers (11% sm1; 44% sm3) were positive (pN1). In summary, although endoscopic resection cannot currently be recommended in cases of Barrett's adenocarcinoma with submucosal infiltration, it is gaining in popularity as a curative technique. [13] [14] [15] [16] Recently, Lin et al 17 demonstrated that the lack or low-intensity staining of AMACR in a cohort of 163 colorectal carcinoma is significantly correlated with poor tumor differentiation (P ¼ 0.021), and presence of lymphovascular invasion (Po0.032). In our study, we did not find a significant correlation between staining score and these criteria.
Several studies have focused on finding molecular markers for reducing interobserver variability in the histopathological diagnosis of Barrett's neoplastic lesions. So far, no reliable prognostic markers for monitoring the neoplastic progression of Barrett's esophagus have been found. As with p53 and p16
INK4A
other molecules-c-erbB2, cyclin D1, p27
KiP1 EGFR, COX-2, and b-catenin-have been found to be disappointing as prognostic markers in Barrett's esophagus. [18] [19] [20] CD1a has also been tested as a possible biomarker of Barrett's metaplasia, in the hope that its expression might help in predicting the prognosis of this pathology. 21 The markers p53 and c-erbB2 in particular have been controversially discussed. TP53 was found to have a low sensitivity, but p53 mutational status may ultimately be a component of such a molecular marker panel. 4, 20 C-erbB2/Her-2/neu could not be demonstrated as a molecular marker by Langer et al 18 but fluorescence in situ hybridization (FISH) analysis demonstrated amplification/overexpression of Her-2/neu as a marker of progression from Barrett's epithelium to dysplasia. 22 The authors suggested that FISH represents a useful diagnostic tool for selecting patients for more targeted therapeutic approaches.
Recently, two studies focused AMACR in Barrett's neoplastic lesions. 7, 8 AMACR is known to be expressed in prostate and colon cancer. Both studies demonstrated the expression of AMACR as a highly specific marker in Barrett's neoplastic lesions. Columnar epithelial cell changes indefinite for dysplasia were positive in 3/30 cases in these studies. Follow-up was available for 11 of these patients with columnar epithelial cell changes indefinite for dysplasia. After 2 months, Barrett's adenocarcinoma was diagnosed in one of the three cases with AMACR immunoreactivity columnar epithelial cell changes indefinite for dysplasia. There was no follow-up in the other two patients. Is AMACR expression also a diagnostic marker for neoplastic transformation in Barrett's disease? We retrospectively analyzed 29 cases with Barrett's adenocarcinoma treated with surgery. Follow-up was at least 12 months. We found 133 different lesions of reactive and neoplastic lesions in Barrett's disease. Previous studies suggested that columnar epithelial cell changes indefinite for dysplasia in Barrett's disease in which AMACR is expressed indicate neoplastic progression of the disease. In the present study, only 27% of columnar epithelial cell changes indefinite for dysplasia demonstrated AMACR expression. Our data are similar to the result from Dorer and Odze 7 concerning columnar epithelial cell changes indefinite for dysplasia ( Interestingly, we demonstrated 90% of low-grade dysplasia to have AMACR immunoreactivity. This is much higher than previously published data, with 10.5% found by Lisovsky et al 8 and 37.5% demonstrated by Dorer and Odze. 7 These differences cannot be explained by method differences, as we used nearly identical methods to Dorer et al. 7 The difference in results concerning low-grade dysplasia might be that our cohort is characterized by dysplasia carcinoma sequence. The sensitivity of AMACR expression in low-grade dysplasia subsequently progressing to early Barrett's adenocarcinoma is significantly higher in our study compared with previous data. Low-grade dysplasia may be transient and does not always progress to cancer. The diagnosis of low-grade dysplasia is difficult, general pathologists are frequently uncertain about the diagnosis of low-grade dysplasia and its follow-up risks. 20 Therefore, AMACR expression in low-grade dysplasia might be a new diagnostic marker in Barrett's disease. Furthermore, lesions classified histologically as 'indefinite' might need to be reclassified after AMACR staining as negative or positive based on the staining pattern. In order to clarify this point, further investigations are needed with a well-defined control group with at least 5-years follow-up.
In conclusion, in our cohort of 29 patients with early Barrett's adenocarcinomas we found much higher rates of AMACR immunoreactivity in neoplastic lesions of Barrett's disease than previous studies demonstrated. We suggest that low-grade dysplasia with AMACR immunoreactivity should be controlled much more frequently by endoscopic biopsy because this might be a new diagnostic parameter in low-grade Barrett's neoplastic lesions. Further studies are needed to investigate this point with well-defined controls having at least 5-years follow-up.
